Amount of suitable clients: CDEC reviewed the uncertainty in the quantity of people with reasonably significant to critical hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical experts consulted by CADTH indicated that some people that are labeled as possessing mild or moderate d